Analysts’ Recent Ratings Updates for Elevance Health (ELV)

Elevance Health (NYSE: ELV) has recently received a number of price target changes and ratings updates:

• 7/17/2026 – Elevance Health had its price target raised by Leerink Partners from $364.00 to $395.00. They now have a “market perform” rating on the stock.
• 7/16/2026 – Elevance Health was given a new $488.00 price target by Sanford C. Bernstein.
• 7/16/2026 – Elevance Health had its price target lowered by Royal Bank Of Canada from $439.00 to $424.00. They now have a “sector perform” rating on the stock.
• 7/16/2026 – Elevance Health had its “neutral” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $395.00 price target on the stock.
• 7/16/2026 – Elevance Health had its price target lowered by Wells Fargo & Company from $492.00 to $473.00. They now have an “overweight” rating on the stock.
• 7/16/2026 – Elevance Health had its price target raised by Robert W. Baird from $331.00 to $393.00. They now have a “neutral” rating on the stock.
• 7/16/2026 – Elevance Health had its price target lowered by Barclays PLC from $480.00 to $457.00. They now have an “overweight” rating on the stock.
• 7/16/2026 – Elevance Health had its price target raised by Guggenheim from $399.00 to $455.00. They now have a “buy” rating on the stock.
• 7/14/2026 – Elevance Health had its price target raised by TD Cowen from $400.00 to $465.00. They now have a “buy” rating on the stock.
• 7/14/2026 – Elevance Health had its price target raised by Truist Financial Corporation from $450.00 to $475.00. They now have a “buy” rating on the stock.
• 7/13/2026 – Elevance Health had its price target raised by Wells Fargo & Company from $391.00 to $492.00. They now have an “overweight” rating on the stock.
• 7/12/2026 – Elevance Health was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/9/2026 – Elevance Health had its price target raised by Royal Bank Of Canada from $358.00 to $439.00. They now have a “sector perform” rating on the stock.
• 7/7/2026 – Elevance Health was given a new $450.00 price target by Raymond James Financial, Inc..
• 7/7/2026 – Elevance Health had its price target raised by Cantor Fitzgerald from $400.00 to $450.00. They now have an “overweight” rating on the stock.
• 7/4/2026 – Elevance Health was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/2/2026 – Elevance Health had its price target raised by Sanford C. Bernstein from $424.00 to $482.00. They now have an “outperform” rating on the stock.
• 6/8/2026 – Elevance Health had its price target raised by Mizuho from $435.00 to $465.00. They now have an “outperform” rating on the stock.
• 6/8/2026 – Elevance Health had its price target raised by JPMorgan Chase & Co. from $411.00 to $476.00. They now have an “overweight” rating on the stock.
• 6/4/2026 – Elevance Health had its price target raised by Bank of America Corporation from $435.00 to $460.00. They now have a “buy” rating on the stock.
• 6/4/2026 – Elevance Health had its price target raised by Morgan Stanley from $352.00 to $404.00. They now have an “equal weight” rating on the stock.
• 6/1/2026 – Elevance Health had its price target raised by Truist Financial Corporation from $375.00 to $450.00. They now have a “buy” rating on the stock.
• 5/26/2026 – Elevance Health had its price target raised by Barclays PLC from $408.00 to $480.00. They now have an “overweight” rating on the stock.

Elevance Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 25th. Stockholders of record on Thursday, September 10th will be given a $1.72 dividend. The ex-dividend date is Thursday, September 10th. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.8%. Elevance Health’s dividend payout ratio is 30.58%.

Insider Activity at Elevance Health

In related news, Director Robert L. Dixon, Jr. sold 151 shares of Elevance Health stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $401.77, for a total transaction of $60,667.27. Following the transaction, the director owned 10,734 shares in the company, valued at approximately $4,312,599.18. This trade represents a 1.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.34% of the company’s stock.

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.